DTIL Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States...

Stats
Dzisiejszy wolumen	78 085.00
Średni wolumen	132 475
Kapitalizacja rynkowa	74.97M
EPS	$0 ( 2024-03-27 )
Następna data zysków	( $-0.450 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.0470 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-26	List Alan	Buy	868	Common Stock
2024-04-30	List Alan	Sell	238	Common Stock
2024-04-26	List Alan	Sell	868	Restricted Stock Units
2024-04-18	Smith J. Jefferson	Buy	31 343	Restricted Stock Units
2024-04-18	Amoroso Michael	Buy	111 217	Restricted Stock Units

INSIDER POWER
35.20
Last 99 transactions
Buy: 6 086 461 \| Sell: 2 083 491

Wolumen Korelacja

Długi: 0.00 (neutral)

Krótki: 0.44 (neutral)

Signal:(62.578) Neutral

Precision BioSciences Inc Korelacja

10 Najbardziej pozytywne korelacje
RMRM	0.953
APOP	0.932
PRPO	0.929
SISI	0.913
XNCR	0.909
CTRM	0.909
OXSQ	0.908
SPTN	0.907
TIL	0.907
AXLA	0.906

10 Najbardziej negatywne korelacje
MMAC	-0.93
OBT	-0.926
ZGNX	-0.918
MPRA	-0.903
ADMS	-0.901
ARNA	-0.898
NETE	-0.898
NCAC	-0.896
NSIT	-0.895
PLPC	-0.894

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Precision BioSciences Inc Korelacja - Waluta/Towar

0.73
( moderate )

0.14
( neutral )

0.00
( neutral )

0.64
( weak )

0.69
( moderate )

0.21
( neutral )

Precision BioSciences Inc Finanse

Annual	2023
Przychody:	$48.73M
Zysk brutto:	$40.47M (83.06 %)
EPS:	$-18.16

FY	2023
Przychody:	$48.73M
Zysk brutto:	$40.47M (83.06 %)
EPS:	$-18.16

FY	2022
Przychody:	$25.10M
Zysk brutto:	$16.09M (64.12 %)
EPS:	$-41.95

FY	2021
Przychody:	$115.53M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Precision BioSciences Inc

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.